Twist Bioscience Corporation (TWST) FY2026 Q3 Statement of Cash Flows

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
Twist Bioscience Corporation cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Stock-based compensation expense → operating reconciliation: $18,176,000.00Accrued compensation → operating reconciliation: $7,869,000.00Depreciation and amortization → operating reconciliation: $6,778,000.00Accounts payable → operating reconciliation: $3,039,000.00Accrued expenses and other liabilities → operating reconciliation: $2,860,000.00Other non-cash adjustments → operating reconciliation: $161,000.00Other non-current assets → operating reconciliation: $114,000.00operating reconciliation → Net cash from operating activities: $1,115,000.00operating reconciliation → Net loss: $35,051,000.00operating reconciliation → Inventories: $1,647,000.00operating reconciliation → Accounts receivable, net: $1,085,000.00operating reconciliation → Prepaid expenses and other current assets: $99,000.00Proceeds from exercise of stock options → financing reconciliation: $3,793,000.00financing reconciliation → Net cash from financing activities: $3,787,000.00financing reconciliation → Repurchases of common stock for income tax withholding: $6,000.00Net cash used in investing activities → investing reconciliation: $10,198,000.00Proceeds from maturity of investments → investing reconciliation: $12,800,000.00investing reconciliation → Purchases of investments: $13,235,000.00investing reconciliation → Purchases of property and equipment: $9,763,000.00Exchange-rate effect → Cash sources and uses: $10,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $124,852,000.00Net cash from operating activities → Cash sources and uses: $1,115,000.00Net cash from financing activities → Cash sources and uses: $3,787,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $119,566,000.00Cash sources and uses → Net cash used in investing activities: $10,198,000.00Stock-based compensation expense: $18,176,000.00Stock-based compensation+$18.18 MPrepaid expenses and other current assets: -$99,000.00Prepaid & other assets−$99.00 KNet loss: -$35,051,000.00Net loss−$35.05 MAccounts receivable, net: -$1,085,000.00Accounts receivable−$1.09 MAccrued compensation: $7,869,000.00Accrued compensation+$7.87 MInventories: -$1,647,000.00Inventories−$1.65 MAccounts payable: $3,039,000.00Accounts payable+$3.04 MOther non-current assets: $114,000.00Other noncurrent assets+$114.00 KDepreciation and amortization: $6,778,000.00Depreciation & amortization+$6.78 MAccrued expenses and other liabilities: $2,860,000.00Accrued & other liabilities+$2.86 MOther non-cash adjustments: $161,000.00Other non-cash items+$161.00 KGain on sale of business: $0.00Net cash from operating activities: $1,115,000.00Operating cash+$1.12 Moperating reconciliation: $38,997,000.00Proceeds from exercise of stock options: $3,793,000.00Employee stock plans & options+$3.79 MRepurchases of common stock for income tax withholding: -$6,000.00Tax withholding repurchases−$6.00 KProceeds from the issuance of liability related to sale of future revenue: $0.00Proceeds from issuance under employee stock purchase plan: $0.00Net cash from financing activities: $3,787,000.00Financing cash+$3.79 Mfinancing reconciliation: $3,793,000.00Purchases of property and equipment: -$9,763,000.00PP&E purchases−$9.76 MPurchase of intangible asset: $0.00Purchases of investments: -$13,235,000.00Investment purchases−$13.24 MProceeds from maturity of investments: $12,800,000.00Investment sales & maturities+$12.80 MCash paid for asset acquisition: $0.00Cash paid for investment in equity securities: $0.00Proceeds from sale of business: $0.00Net cash used in investing activities: -$10,198,000.00. Cash required to fund net payments.Investing cash−$10.20 Minvesting reconciliation: $22,998,000.00Cash sources and uses: $129,764,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $124,852,000.00Beginning cash$124.85 MEnding cash: Cash, cash equivalents, and restricted cash: $119,566,000.00Ending cash$119.57 MExchange-rate effect: $10,000.00FX effect+$10.00 KCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsNet loss −$35.05M + net operating adjustments $36.17M = operating cash +$1.12MFree cash flow−$8.65 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$5.29 MEnding cash − beginning cash
Chart details

Twist Bioscience Corporation cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
124,852,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
1,115,000 US dollars. Net cash provided.
Stock-based compensation expense
18,176,000 US dollars
Prepaid expenses and other current assets
negative 99,000 US dollars
Net loss
negative 35,051,000 US dollars
Accounts receivable, net
negative 1,085,000 US dollars
Accrued compensation
7,869,000 US dollars
Inventories
negative 1,647,000 US dollars
Accounts payable
3,039,000 US dollars
Other non-current assets
114,000 US dollars
Depreciation and amortization
6,778,000 US dollars
Accrued expenses and other liabilities
2,860,000 US dollars
Other non-cash adjustments
161,000 US dollars
Gain on sale of business
0 US dollars
Investing activities
negative 10,198,000 US dollars. Net cash used.
Purchases of property and equipment
negative 9,763,000 US dollars
Purchase of intangible asset
0 US dollars
Purchases of investments
negative 13,235,000 US dollars
Proceeds from maturity of investments
12,800,000 US dollars
Cash paid for asset acquisition
0 US dollars
Cash paid for investment in equity securities
0 US dollars
Proceeds from sale of business
0 US dollars
Financing activities
3,787,000 US dollars. Net cash provided.
Proceeds from exercise of stock options
3,793,000 US dollars
Repurchases of common stock for income tax withholding
negative 6,000 US dollars
Proceeds from the issuance of liability related to sale of future revenue
0 US dollars
Proceeds from issuance under employee stock purchase plan
0 US dollars
Operating adjustment reconciliation
38,997,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
3,793,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
22,998,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
10,000 US dollars
Ending cash on Jun 30, 2026
119,566,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
129,764,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 5,286,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
1,115,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
9,763,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 8,648,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$35.05M + net operating adjustments $36.17M = operating cash +$1.12M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 1,115,000 US dollars minus 9,763,000 US dollars equals negative 8,648,000 US dollars.
Twist Bioscience Corporation (TWST) FY2026 Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!